BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33749648)

  • 1. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
    Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
    J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain.
    Marutle A; Gillberg PG; Bergfors A; Yu W; Ni R; Nennesmo I; Voytenko L; Nordberg A
    J Neuroinflammation; 2013 Jul; 10():90. PubMed ID: 23880036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
    Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
    Ni R; Gillberg PG; Bergfors A; Marutle A; Nordberg A
    Brain; 2013 Jul; 136(Pt 7):2217-27. PubMed ID: 23757761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
    Rodriguez-Vieitez E; Kumar A; Malarte ML; Ioannou K; Rocha FM; Chiotis K
    Methods Mol Biol; 2024; 2785():195-218. PubMed ID: 38427196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.
    Fodero-Tavoletti MT; Brockschnieder D; Villemagne VL; Martin L; Connor AR; Thiele A; Berndt M; McLean CA; Krause S; Rowe CC; Masters CL; Dinkelborg L; Dyrks T; Cappai R
    Nucl Med Biol; 2012 Oct; 39(7):1042-8. PubMed ID: 22503458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitracer Approach to Understanding the Complexity of Reactive Astrogliosis in Alzheimer's Brains.
    Fontana IC; Kumar A; Okamura N; Nordberg A
    ACS Chem Neurosci; 2024 Jan; 15(2):328-336. PubMed ID: 38133820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
    Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
    Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
    Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
    Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A
    Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.